Score molecules upfront and suggest changes that lower aggregation and other CMC liabilities before any wet lab work.
Models that recommend cell line, media, and bioprocess conditions to hit yield and quality targets faster.
Predict how the process behaves across scales and operating ranges to de-risk transfer and tech ops.
Final, wet-lab-validated assets handed back: candidate, process, and characterization data ready for scale-up.
AbInitio joined Y Combinator, the world's leading startup accelerator. See our launch and company profile on the YC directory.
AbInitio was selected for MIT's R2E program, which provides funding, mentorship, and resources to translate breakthrough biomedical research into scalable ventures.
AbInitio was chosen for the 5050 program by Fifty Years, a venture fund that backs founders building companies to solve the world's biggest problems through science and technology.
Join the pharma and biotech teams partnering with AbInitio to cut months off the path from candidate to commercial scale.
Get in Touch